drugset / Trial / NCT05034536
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Phase 2
Active not recruiting
36 enrolled
Massachusetts General Hospital
Massachusetts Institute of Technology · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.
Timeline
- Start
- 2022-02-07
- Primary completion
- 2026-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | — | Intravenous |